Recent News

• 10.29.2025 - Aclaris Therapeutics to Participate in Three November Healthcare Conferences
• 10.14.2025 - 2025 R&D Day
• 09.30.2025 - Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
• 09.30.2025 - Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
• 09.09.2025 - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
• 09.03.2025 - Cantor Global Healthcare Conference
• 08.27.2025 - Aclaris Therapeutics to Participate in Two September Healthcare Conferences
• 08.27.2025 - Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Recent Filings

• 10.14.2025 - EX-99.1 EX-99.1
• 10.14.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 08.07.2025 - EX-99.1 EX-99.1
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2025 - 3 Initial statement of beneficial ownership of securities